Collegium Pharmaceutical (COLL) financial statements
Collegium Pharmaceutical reported revenue of $781M in fiscal 2025, up 97.5% a year over 9 years.
Net income was $63M and the operating margin 23.0%, against -5498.7% in 2016.
Free cash flow was $328M, and the company returned $25M in net buybacks.
The diluted share count rose 64% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Collegium Pharmaceutical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $28M | $280M | $297M | $310M | $277M | $464M | $567M | $631M | $781M |
| Cost of revenue | $213,000 | $3M | $166M | $194M | $130M | $126M | $254M | $241M | $254M | $317M |
| Gross profit | $1M | $26M | $115M | $103M | $180M | $151M | $209M | $326M | $377M | $463M |
| Research and development | $15M | $9M | $9M | $10M | $10M | $9M | $4M | $0 | $0 | — |
| Selling, general and admin | $81M | $93M | $127M | $116M | $114M | $119M | $172M | $159M | $210M | $285M |
| Operating income | -$94M | -$75M | -$21M | -$24M | $56M | $18M | $33M | $167M | $170M | $180M |
| Interest expense | $94,000 | — | $20M | $909,000 | $29M | $21M | $63M | $83M | $74M | $82M |
| Pre-tax income | — | — | -$39M | -$23M | $28M | -$3M | -$29M | $76M | $99M | $93M |
| Income tax | — | — | — | $0 | $830,000 | -$75M | -$4M | $28M | $29M | $30M |
| Net income | -$94M | -$75M | -$39M | -$23M | $27M | $72M | -$25M | $48M | $69M | $63M |
| EPS (diluted) | -$3.88 | -$2.47 | -$1.19 | -$0.68 | $0.76 | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Diluted shares | 24M | 30M | 33M | 33M | 35M | 41M | 34M | 42M | 40M | 40M |
| Gross margin | 87.6% | 90.9% | 40.9% | 34.7% | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| Operating margin | -5498.7% | -264.9% | -7.4% | -8.0% | 18.1% | 6.4% | 7.2% | 29.5% | 26.9% | 23.0% |
| Net margin | -5504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
Balance sheet
Fiscal years, from Collegium Pharmaceutical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $153M | $119M | $147M | $170M | $174M | $186M | $174M | $311M | $163M | $387M |
| Receivables | $2M | $10M | $78M | $73M | $83M | $106M | $183M | $180M | $229M | $211M |
| Inventory | $1M | $2M | $8M | $10M | $16M | $17M | $47M | $32M | $36M | $41M |
| Total current assets | $159M | $133M | $238M | $256M | $278M | $316M | $420M | $538M | $482M | $691M |
| Property, plant and equipment | $1M | $2M | $9M | $12M | $19M | $19M | $20M | $16M | $14M | $12M |
| Goodwill | — | — | — | — | — | — | $134M | $134M | $162M | $146M |
| Total assets | $162M | $136M | $291M | $306M | $644M | $692M | $1.2B | $1.1B | $1.7B | $1.7B |
| Total current liabilities | $26M | $31M | $189M | $202M | $239M | $280M | $434M | $458M | $510M | $440M |
| Total liabilities | $27M | $31M | $200M | $219M | $458M | $489M | $979M | $948M | $1.4B | $1.4B |
| Shareholders' equity | $135M | $104M | $92M | $87M | $186M | $203M | $195M | $195M | $229M | $302M |
| Net debt | -$153M | -$119M | -$147M | -$170M | -$174M | -$186M | -$174M | -$239M | -$71M | -$231M |
Cash flow
Fiscal years, from Collegium Pharmaceutical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75M | -$67M | $169M | $28M | $94M | $104M | $124M | $275M | $205M | $329M |
| Capital spending | $477,000 | $990,000 | $5M | $6M | $6M | $2M | $2M | $461,000 | $2M | $2M |
| Free cash flow | -$76M | -$68M | $164M | $21M | $88M | $102M | $123M | $274M | $203M | $328M |
| Stock-based compensation | $6M | $8M | $14M | $17M | $22M | $24M | $23M | $27M | $32M | $42M |
| Share buybacks (net) | — | — | — | — | — | -$48M | -$14M | -$75M | -$60M | -$25M |
| Net borrowing | -$3M | -$3M | $10M | — | -$12M | — | — | — | — | — |
| Free cash flow margin | -4414.4% | -238.8% | 58.5% | 7.2% | 28.5% | 36.7% | 26.4% | 48.4% | 32.2% | 42.0% |
Questions
What was Collegium Pharmaceutical's revenue in 2025?
$781M in fiscal 2025, from its 10-K filing.
How much free cash flow does Collegium Pharmaceutical generate?
$328M in fiscal 2025 (operating cash flow minus capital spending).
From Collegium Pharmaceutical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.